Inspirna, Inc. is a biopharmaceutical company based in New York City that discovers and develops drug candidates that target novel cancer pathways. The company uses RNA-DRIVER, a miRNA based platform that reveals multiple critical drivers that can be drugged by novel small molecule and biologic therapeutics. Inspirna's lead program in Phase 1b/2 clinical development is ompenaclid (RGX-202), an oral small molecule SLC6A8 inhibitor for the treatment of pan-RAS mutant colorectal cancer. In addition, the company develops abequolixron (RGX-104), an oral small molecule LXR agonist for the treatment of metastatic NSCLC and endometrial cancer, in collaboration with Bristol Myers Squibb, and RGX-019, an Antibody Drug Conjugate (ADC) that targets a key pathway (TAM) that drives tumor progression and metastasis of several cancer types. Inspirna, Inc. was formerly known as Rgenix, Inc.